Annual FCF
-$17.14 M
-$3.45 M-25.17%
December 1, 2023
Summary
- As of February 7, 2025, CSCI annual free cash flow is -$17.14 million, with the most recent change of -$3.45 million (-25.17%) on December 1, 2023.
- During the last 3 years, CSCI annual FCF has fallen by -$13.01 million (-315.04%).
- CSCI annual FCF is now -255.41% below its all-time high of $11.03 million, reached on December 1, 2005.
Performance
CSCI Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
-$7.91 M
-$6.36 M-410.03%
September 1, 2024
Summary
- As of February 7, 2025, CSCI quarterly free cash flow is -$7.91 million, with the most recent change of -$6.36 million (-410.03%) on September 1, 2024.
- Over the past year, CSCI quarterly FCF has dropped by -$6.07 million (-330.29%).
- CSCI quarterly FCF is now -247.29% below its all-time high of $5.37 million, reached on June 1, 1997.
Performance
CSCI Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
-$14.26 M
-$8.01 M-127.99%
September 1, 2024
Summary
- As of February 7, 2025, CSCI TTM free cash flow is -$14.26 million, with the most recent change of -$8.01 million (-127.99%) on September 1, 2024.
- Over the past year, CSCI TTM FCF has dropped by -$10.79 million (-310.90%).
- CSCI TTM FCF is now -393.93% below its all-time high of $4.85 million, reached on March 1, 1998.
Performance
CSCI TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
CSCI Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -25.2% | -330.3% | -310.9% |
| 3 y3 years | -315.0% | -330.3% | -310.9% |
| 5 y5 years | -351.4% | -330.3% | -310.9% |
CSCI Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -85.9% | at low | -497.7% | at low | -409.8% | at low |
| 5 y | 5-year | -315.0% | at low | -497.7% | at low | -409.8% | at low |
| alltime | all time | -255.4% | +49.4% | -247.3% | +61.3% | -393.9% | +30.2% |
COSCIENS Biopharma Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$7.91 M(+410.0%) | -$14.26 M(+128.0%) |
| Jun 2024 | - | -$1.55 M(-47.6%) | -$6.25 M(+12.3%) |
| Mar 2024 | - | -$2.96 M(+61.0%) | -$5.57 M(+60.5%) |
| Dec 2023 | -$17.14 M(+25.2%) | -$1.84 M(-2035.1%) | -$3.47 M(+278.6%) |
| Sep 2023 | - | $95.00 K(-111.0%) | -$916.70 K(>+9900.0%) |
| Jun 2023 | - | -$866.90 K(+0.8%) | -$8900.00(-100.3%) |
| Mar 2023 | - | -$860.10 K(-220.2%) | $2.85 M(-38.2%) |
| Dec 2022 | -$13.69 M(+48.5%) | $715.30 K(-28.7%) | $4.60 M(+7.9%) |
| Sep 2022 | - | $1.00 M(-49.6%) | $4.26 M(+26.4%) |
| Jun 2022 | - | $1.99 M(+121.9%) | $3.37 M(+9.9%) |
| Mar 2022 | - | $896.50 K(+138.2%) | $3.07 M(+39.6%) |
| Dec 2021 | -$9.22 M(+123.3%) | $376.30 K(+238.4%) | $2.20 M(+54.1%) |
| Sep 2021 | - | $111.20 K(-93.4%) | $1.43 M(-48.8%) |
| Jun 2021 | - | $1.68 M(+6427.5%) | $2.78 M(+4.2%) |
| Mar 2021 | - | $25.80 K(-106.5%) | $2.67 M(-11.1%) |
| Dec 2020 | -$4.13 M(-61.5%) | -$395.60 K(-126.9%) | $3.01 M(-2.3%) |
| Sep 2020 | - | $1.47 M(-6.4%) | $3.08 M(+74.8%) |
| Jun 2020 | - | $1.57 M(+335.9%) | $1.76 M(+218.4%) |
| Mar 2020 | - | $360.50 K(-210.8%) | $552.90 K(+32.7%) |
| Dec 2019 | -$10.72 M(-257.4%) | -$325.50 K(-311.4%) | $416.50 K(-161.3%) |
| Sep 2019 | - | $154.00 K(-57.7%) | -$679.70 K(-58.0%) |
| Jun 2019 | - | $363.90 K(+62.4%) | -$1.62 M(-29.3%) |
| Mar 2019 | - | $224.10 K(-115.8%) | -$2.29 M(-7.8%) |
| Dec 2018 | $6.82 M(-129.7%) | -$1.42 M(+81.3%) | -$2.48 M(+59.4%) |
| Sep 2018 | - | -$784.20 K(+156.9%) | -$1.56 M(+326.8%) |
| Jun 2018 | - | -$305.20 K(-1065.8%) | -$364.50 K(-58.4%) |
| Mar 2018 | - | $31.60 K(-106.3%) | -$876.90 K(-54.9%) |
| Dec 2017 | -$22.92 M(-21.2%) | -$498.00 K(-222.3%) | -$1.94 M(+40.8%) |
| Sep 2017 | - | $407.10 K(-149.8%) | -$1.38 M(-20.6%) |
| Jun 2017 | - | -$817.60 K(-21.1%) | -$1.74 M(+4.9%) |
| Mar 2017 | - | -$1.04 M(-1672.5%) | -$1.66 M(+2222.4%) |
| Dec 2016 | -$29.08 M(-14.2%) | $65.90 K(+34.2%) | -$71.40 K(-115.2%) |
| Sep 2016 | - | $49.10 K(-106.7%) | $470.90 K(+29.3%) |
| Jun 2016 | - | -$736.90 K(-233.9%) | $364.10 K(-58.9%) |
| Mar 2016 | - | $550.50 K(-9.5%) | $885.70 K(-650.5%) |
| Dec 2015 | -$33.87 M(+8.5%) | $608.20 K(-1154.1%) | -$160.90 K(-81.8%) |
| Sep 2015 | - | -$57.70 K(-73.2%) | -$885.10 K(+9.1%) |
| Jun 2015 | - | -$215.30 K(-56.6%) | -$811.00 K(-47.3%) |
| Mar 2015 | - | -$496.10 K(+327.7%) | -$1.54 M(-28.1%) |
| Dec 2014 | -$31.21 M(+55.5%) | -$116.00 K(-807.3%) | -$2.14 M(-35.1%) |
| Sep 2014 | - | $16.40 K(-101.7%) | -$3.30 M(-6.8%) |
| Jun 2014 | - | -$942.90 K(-14.1%) | -$3.54 M(+37.9%) |
| Mar 2014 | - | -$1.10 M(-13.7%) | -$2.56 M(+50.6%) |
| Dec 2013 | -$20.07 M(-35.4%) | -$1.27 M(+468.6%) | -$1.70 M(+128.7%) |
| Sep 2013 | - | -$223.80 K(-848.5%) | -$744.70 K(+115.5%) |
| Jun 2013 | - | $29.90 K(-112.6%) | -$345.50 K(-25.3%) |
| Mar 2013 | - | -$236.50 K(-24.8%) | -$462.50 K(+27.4%) |
| Dec 2012 | -$31.09 M(+14.9%) | -$314.30 K(-279.2%) | -$363.10 K(-266.2%) |
| Sep 2012 | - | $175.40 K(-301.4%) | $218.50 K(+526.1%) |
| Jun 2012 | - | -$87.10 K(-36.5%) | $34.90 K(-84.9%) |
| Mar 2012 | - | -$137.10 K(-151.3%) | $231.30 K(-65.4%) |
| Dec 2011 | -$27.05 M(-14.9%) | $267.30 K(-3359.8%) | $668.30 K(+62.8%) |
| Sep 2011 | - | -$8200.00(-107.5%) | $410.50 K(-52.5%) |
| Jun 2011 | - | $109.30 K(-63.6%) | $863.90 K(+26.6%) |
| Mar 2011 | - | $299.90 K(+3056.8%) | $682.60 K(+75.7%) |
| Dec 2010 | -$31.79 M | $9500.00(-97.9%) | $388.40 K(+4031.9%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2010 | - | $445.20 K(-718.3%) | $9400.00(-101.6%) |
| Jun 2010 | - | -$72.00 K(-1363.2%) | -$579.20 K(-33.0%) |
| Mar 2010 | - | $5700.00(-101.5%) | -$865.00 K(-11.3%) |
| Dec 2009 | -$24.93 M(+902.7%) | -$369.50 K(+157.7%) | -$975.10 K(+54.2%) |
| Sep 2009 | - | -$143.40 K(-59.9%) | -$632.30 K(+105.5%) |
| Jun 2009 | - | -$357.80 K(+242.7%) | -$307.70 K(-12.7%) |
| Mar 2009 | - | -$104.40 K(+291.0%) | -$352.40 K(-69.6%) |
| Dec 2008 | -$2.49 M(-91.5%) | -$26.70 K(-114.7%) | -$1.16 M(-48.9%) |
| Sep 2008 | - | $181.20 K(-145.0%) | -$2.27 M(-31.2%) |
| Jun 2008 | - | -$402.50 K(-55.9%) | -$3.31 M(-7.4%) |
| Mar 2008 | - | -$912.80 K(-19.9%) | -$3.57 M(+31.5%) |
| Dec 2007 | -$29.30 M(-583.6%) | -$1.14 M(+33.8%) | -$2.71 M(+77.9%) |
| Sep 2007 | - | -$851.10 K(+27.7%) | -$1.53 M(+37.3%) |
| Jun 2007 | - | -$666.60 K(+1043.4%) | -$1.11 M(+500.7%) |
| Mar 2007 | - | -$58.30 K(-216.4%) | -$185.00 K(-350.3%) |
| Dec 2006 | $6.06 M(-45.1%) | $50.10 K(-111.5%) | $73.90 K(-148.3%) |
| Sep 2006 | - | -$436.50 K(-268.1%) | -$153.10 K(-166.7%) |
| Jun 2006 | - | $259.70 K(+29.5%) | $229.70 K(-441.8%) |
| Mar 2006 | - | $200.60 K(-213.4%) | -$67.20 K(-85.8%) |
| Dec 2005 | $11.03 M(+34.1%) | -$176.90 K(+229.4%) | -$473.10 K(-10.7%) |
| Sep 2005 | - | -$53.70 K(+44.4%) | -$529.90 K(-12.8%) |
| Jun 2005 | - | -$37.20 K(-81.9%) | -$607.60 K(-3.4%) |
| Mar 2005 | - | -$205.30 K(-12.2%) | -$628.90 K(+32.8%) |
| Dec 2004 | $8.22 M(-174.1%) | -$233.70 K(+77.9%) | -$473.60 K(+26.0%) |
| Sep 2004 | - | -$131.40 K(+124.6%) | -$376.00 K(+71.5%) |
| Jun 2004 | - | -$58.50 K(+17.0%) | -$219.20 K(+64.2%) |
| Mar 2004 | - | -$50.00 K(-63.3%) | -$133.50 K(+174.1%) |
| Dec 2003 | -$11.10 M(-35.4%) | -$136.10 K(-635.8%) | -$48.70 K(-41.7%) |
| Sep 2003 | - | $25.40 K(-6.6%) | -$83.60 K(-4.0%) |
| Jun 2003 | - | $27.20 K(-21.8%) | -$87.10 K(-31.3%) |
| Mar 2003 | - | $34.80 K(-120.4%) | -$126.70 K(-30.6%) |
| Dec 2002 | -$17.18 M(+66.6%) | -$171.00 K(-880.8%) | -$182.50 K(+351.7%) |
| Sep 2002 | - | $21.90 K(-276.6%) | -$40.40 K(+50.7%) |
| Jun 2002 | - | -$12.40 K(-41.0%) | -$26.80 K(-88.7%) |
| Mar 2002 | - | -$21.00 K(-27.3%) | -$237.00 K(-48.2%) |
| Dec 2001 | -$10.31 M(+116.0%) | -$28.90 K(-181.4%) | -$457.40 K(-4.6%) |
| Sep 2001 | - | $35.50 K(-115.9%) | -$479.60 K(-18.4%) |
| Jun 2001 | - | -$222.60 K(-7.8%) | -$587.40 K(-7.1%) |
| Mar 2001 | - | -$241.40 K(+372.4%) | -$632.20 K(+19.6%) |
| Dec 2000 | -$4.77 M(-34.5%) | -$51.10 K(-29.3%) | -$528.50 K(-3.8%) |
| Sep 2000 | - | -$72.30 K(-73.0%) | -$549.30 K(+0.7%) |
| Jun 2000 | - | -$267.40 K(+94.2%) | -$545.60 K(+57.0%) |
| Mar 2000 | - | -$137.70 K(+91.5%) | -$347.60 K(+25.9%) |
| Dec 1999 | -$7.28 M(+25.9%) | -$71.90 K(+4.8%) | -$276.20 K(-38.9%) |
| Sep 1999 | - | -$68.60 K(-1.2%) | -$452.30 K(-73.2%) |
| Jun 1999 | - | -$69.40 K(+4.7%) | -$1.69 M(+4.8%) |
| Mar 1999 | - | -$66.30 K(-73.3%) | -$1.61 M(-8.3%) |
| Dec 1998 | -$5.78 M(+112.2%) | -$248.00 K(-81.0%) | -$1.75 M(+26.3%) |
| Sep 1998 | - | -$1.30 M(<-9900.0%) | -$1.39 M(+171.2%) |
| Jun 1998 | - | $7100.00(-103.4%) | -$512.10 K(-110.6%) |
| Mar 1998 | - | -$211.30 K(-279.5%) | $4.85 M(-131.6%) |
| Dec 1997 | -$2.73 M(+433.6%) | $117.70 K(-127.7%) | -$15.37 M(-0.8%) |
| Sep 1997 | - | -$425.60 K(-107.9%) | -$15.49 M(+2.8%) |
| Jun 1997 | - | $5.37 M(-126.3%) | -$15.07 M(-26.3%) |
| Mar 1997 | - | -$20.44 M | -$20.44 M |
| Dec 1996 | -$510.80 K | - | - |
FAQ
- What is COSCIENS Biopharma annual free cash flow?
- What is the all time high annual FCF for COSCIENS Biopharma?
- What is COSCIENS Biopharma annual FCF year-on-year change?
- What is COSCIENS Biopharma quarterly free cash flow?
- What is the all time high quarterly FCF for COSCIENS Biopharma?
- What is COSCIENS Biopharma quarterly FCF year-on-year change?
- What is COSCIENS Biopharma TTM free cash flow?
- What is the all time high TTM FCF for COSCIENS Biopharma?
- What is COSCIENS Biopharma TTM FCF year-on-year change?
What is COSCIENS Biopharma annual free cash flow?
The current annual FCF of CSCI is -$17.14 M
What is the all time high annual FCF for COSCIENS Biopharma?
COSCIENS Biopharma all-time high annual free cash flow is $11.03 M
What is COSCIENS Biopharma annual FCF year-on-year change?
Over the past year, CSCI annual free cash flow has changed by -$3.45 M (-25.17%)
What is COSCIENS Biopharma quarterly free cash flow?
The current quarterly FCF of CSCI is -$7.91 M
What is the all time high quarterly FCF for COSCIENS Biopharma?
COSCIENS Biopharma all-time high quarterly free cash flow is $5.37 M
What is COSCIENS Biopharma quarterly FCF year-on-year change?
Over the past year, CSCI quarterly free cash flow has changed by -$6.07 M (-330.29%)
What is COSCIENS Biopharma TTM free cash flow?
The current TTM FCF of CSCI is -$14.26 M
What is the all time high TTM FCF for COSCIENS Biopharma?
COSCIENS Biopharma all-time high TTM free cash flow is $4.85 M
What is COSCIENS Biopharma TTM FCF year-on-year change?
Over the past year, CSCI TTM free cash flow has changed by -$10.79 M (-310.90%)